Home / Research projects / L. CASEI DG® (LACTOBACILLUS PARACASEI CNCMI1572; ENTEROLACTIS®PLUS) IN THE TREATMENT OF PATIENTS WITH IRRITABLE BOWEL SYNDROME: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLELGROUP, PLACEBO CONTROLLED STUDY
Share
L. CASEI DG® (LACTOBACILLUS PARACASEI CNCMI1572; ENTEROLACTIS®PLUS) IN THE TREATMENT OF PATIENTS WITH IRRITABLE BOWEL SYNDROME: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLELGROUP, PLACEBO CONTROLLED STUDY
L. CASEI DG® (LACTOBACILLUS PARACASEI CNCMI1572; ENTEROLACTIS® PLUS) in the treatment of patients with irritable bowel syndrome; a multicenter, randomized, double-blind, parallel-group, placebo-controlled study.
Project objectives
The overall aim of the study was to collect data to evaluate the effect of Lactobacillus casei DG (Enterolactis plus®) on abdominal symptoms in non-constipated patients with IBS.
Start and end date
2017 - ongoing
Project Manager
Prof. Michele Cicala
Coordinating institution of the project
Complex Operating Unit of Gastroenterology, Biomedical Campus University of Rome
L'Università Campus Bio-Medico di Roma promotes integrated teaching and research structures, pursuing the good of the person as the main aim of its activities.
